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Background: Two experimental studies using a transmission blocking model with Dermacentor reticulatus ticks
infected with Babesia canis were performed to test the ability of Effitix® to prevent the transmission of babesiosis in
dogs.
Methods: Four groups of seven dogs (experiment 1) and one group of eight dogs (experiment 2) were treated
topically with a novel combination of fipronil and permethrin in a spot-on formulation (Effitix®, Virbac) respectively
28, 21, 14 and 7 days (experiment 1) and 2 days (experiment 2) prior to tick infestation. In each study, a control
group of seven dogs (experiment 1) and eight dogs (experiment 2) remained untreated. On day 0, all dogs were
infested with adult D.reticulatus ticks harboring B. canis. An efficacy failure (successfully infected) was regarded as a
dog in the treated groups that was tested serologically positive for B.canis antibodies, using an indirect fluorescent
antibody (IFA) assay and tested positive for B.canis by DNA-assay using PCR analysis.
Results: B.canis was transmitted by D.reticulatus to all untreated dogs (experiment 1) and six untreated dogs out of
eight (experiment 2) as confirmed by IFA and PCR assays. The large majority of treated dogs (92.9% in experiment 1
and 100% in experiment 2) remained sero-negative over the challenge period.
Conclusions: The treatment of dogs with Effitix® applied 2 to 28 days prior to infestation with D. reticulatus
harboring B.canis, successfully prevented the transmission of canine babesiosis.
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blockingBackground
Canine babesiosis is a tick-borne protozoan disease of
worldwide significance. The main clinical signs described
in dogs are lethargy, anorexia, hyperthermia (≥39°C)
followed by pale mucous membranes, discoloration of
the urine and splenomegaly [1]. The most frequent
causative agent of canine babesiosis in Central Europe
is Babesia canis. This parasite is an intraerythrocytic* Correspondence: christelle.navarro@virbac.com
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unless otherwise stated.protozoa which activates antibody-mediated cytotoxic
destruction of erythrocytes leading to death, in case of
massive infection [2]. Historically, Babesia parasites in
dogs were divided into two groups based on morpho-
logical distinction: the larger B.canis and the smaller
Babesia gibsoni. Based on cross-immunity and vector-
specificity, B.canis has been then reclassified into three
subspecies: B. canis canis, B.canis rossi and B.canis
vogeli. They are now considered as three separate species:
B.canis, B.rossi and B.vogeli [3].
The incidence of clinical babesiosis varies amongst
countries and regions in Europe. B.canis was historicallyl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Categorization of ticks for counting (adapted
from EMEA/CVMP/005/00Final-Rev.2) [19]
Category General findings Attachment status
1 Live Free
2 Live Attached; unengorged*
3 Live Attached; engorged**
4 Dead Free
5 Dead Attached; unengorged
6 Dead Attached; engorged
*No filling of the alloscutum evident.
**Obvious or conspicuous filling of the alloscutum evident.
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disease is endemic with an overall presence of babesiosis
due to B.canis with nevertheless local variations. In
Spain and Hungary B.canis is endemic with several spe-
cies of piroplasms co-existing in Spain. In Romania, a re-
cent survey has indicated that infection with B.canis in
dogs is common, and that it is an important pathogen
for the local canine population. In Italy, a high sero-
prevalence of B.canis was shown in kenneled dogs. How-
ever, the custom of traveling with family pets or hunting
dogs on trips to distant regions and returning home has
led to an alarming increase in reports of canine vector-
borne pathogens in northern and cooler regions of
mainland Europe where these diseases were previously
unreported. In the United Kingdom, Benelux, Germany,
Switzerland and Austria, imported cases or small au-
tochthonous foci of B.canis infection have been reported
even if there is so far an overall low prevalence of the
disease [3-9]. This adds to the relevance of practicing ef-
fective tick control on dogs.
Effitix® is a combination of two active ingredients fipro-
nil 6.1% and permethrin 54.5% (w/v) in a solution for top-
ical application (spot-on). Fipronil has well-established
insecticidal and acaricidal properties [10]; permethrin
brings to the combination its strong repellent effects
resulting in absence or reduction of the blood feeding
(anti-feeding effect) [11-13].
In the two studies presented below, we tested the abil-
ity of Effitix® to prevent transmission of B.canis to dogs
based on an experimental model recently described in
the literature [14-17] and developed to assess the effi-
cacy in preventing the transmission of tick-borne patho-




The two studies were conducted according to the Inter-
national Cooperation on Harmonization of Technical
Requirements for Registration of Veterinary Medicinal
Products Guideline (VICH GL9): Good Clinical Practice
[18]and in compliance with local animal welfare legisla-
tion. They were performed at the same test facilities in
South Africa and followed very similar but complemen-
tary protocols. The two protocols were approved by the
ClinVet animal ethics committee (references CV12/949
and CV13/091). Both studies investigated the efficacy of
Effitix® in reducing the transmission of B.canis, from two
days (Experiment 2) up to 28 days (Experiment 1) after
application.
Study design, animal selection and treatment
The studies were parallel group designed, randomized,
controlled, blinded and experimental efficacy studies. Inorder to control bias, the products were not adminis-
tered by an individual involved in performing the post-
administration assessments and observations. The dogs
were randomly allocated to group according to their
body weight within gender at inclusion. All dogs were
dewormed and did not harbour any ticks at the initiation
of the study. At least during the 12 weeks preceding the
treatment, the dogs had not been treated with a long
acting topical or systemic acaricide/insecticide. They
were sero-negative for B.canis prior to initiation of accli-
matisation. Animals were treated once at two spots
(equal volumes), one between the shoulder blades and
the second at the lumbar area directly to the skin. The
size of the pipette of the product to apply was chosen
according to the body weight of the dog and followed
the label recommendations i.e. one 1.1 ml pipette of
fipronil 6.1% and 54.5% permethrin (w/v) solution for
dogs weighing >4-10 kg, one 2.2 ml pipette for dogs
weighing >10-20 kg, one 4.4 ml pipette for dogs weigh-
ing >20-40 kg.
Tick challenges
A laboratory-bred D.reticulatus tick strain, infected with
B.canis, was used for the artificial challenges. A sample
of 50 ticks was taken from the batch of ticks used for
artificial challenges and the infectivity confirmed by PCR
analysis. On day 0, each dog was infested with 50 (±4)
viable, unfed adult D.reticulatus with a balanced sex ra-
tio (50% female:50% male). Ticks were applied directly
onto the dog by tapping the vial to dislodge the ticks
from the container so that they were placed or spread
directly over the dog’s hair coat. Dogs were restrained
for 10 minutes and confined in an infestation chamber
to enhance tick attachment for approximately four
hours. Ticks dislodged during the first 10 minutes were
placed back onto the dog.
Tick counts
Following infestation, in situ thumb counts were per-
formed regularly. The number of ticks was recorded by
tick categories (Table 1) in order to determine the
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preventing the establishment of tick infestation and evalu-
ate their engorgement status. On day 6 post-infestation,
the ticks were counted, removed and categorized. Follow-
ing the final day 6 tick count assessments, the cage was
cleaned and sprayed with an acaricide to rid the environ-
ment of any possible persistent tick infestations.
Acaricidal efficacy
Efficacy against ticks was calculated for the administration
group at each assessment day according to the formulas
given below. The calculations were based on the arith-
metic or geometric means of the tick counts.
Efficacy (%) = 100 × (Mc – Mt)/Mc, where:
Mc = Arithmetic or geometric mean number of live
ticks (categories 1 to 3) on dogs in the negative control
group at a specific time point.
Mt = Arithmetic or geometric mean number of live
ticks (categories 1 to 3) in the treatment group at a
specific time point.
The groups were compared using an ANOVA with a
treatment effect after a logarithmic transformation on
the tick (count + 1) data.
Methods for Babesia canis detection
Blood smear
In case of clinical suspicion (body temperature > 39.4°C),
two blood smears were prepared from a small drop of
peripheral blood collected from the tip of the ear, tip of
the tail or other suitable area by cutting or stabbing the
skin using a new hypodermic needle. The blood smear
was examined to search for intraerythrocytic piroplasms.
PCR analysis
Blood collected (whole blood >3.5 ml) for PCR analysis
was collected in EDTA tubes. Prior to starting the pro-
cedure, approximately 1 mL of blood was taken from the
whole blood sample and stored in a cryo tube in a −30°C
freezer which served as a secondary sample for PCR
analysis.
The remaining whole blood samples were transferred
to the ClinVet molecular laboratory for analysis. Total
genomic DNA was isolated from whole blood samples,
using a commercial genomic DNA isolation kit. Poly-
merase chain reaction entailed the use of primers spe-
cific to a region of the B. canis rDNA (17). Up to 400 ng
isolated DNA served as template for PCR amplification
of the target region. PCR products were analyzed using
agarose gel electrophoresis and documented. A PCR
product of approximately 300 bp indicated the presence
of the B.canis rDNA target region in the sample.Positive, negative, no template, as well as internal ampli-
fication controls, were included in each run.
IFA test
At least 3 mL of blood was collected from all dogs.
Serum was recovered from the plain tubes and divided
into primary and duplicate aliquots. Primary aliquots
were stored at 2°C to 8°C for two days until assayed for
B.canis antibodies, using a commercial IFA test. Dupli-
cate aliquots were frozen at < −35°C. If primary aliquots
were not analyzed within two days after blood collection,
these aliquots were frozen at < −35°C until analysis.
Methods for calculating the B.canis blocking effectiveness
An efficacy failure (successfully infected) was regarded
as a dog in the Effitix® administration group that was
tested serologically positive for B.canis antibodies and
positive for B.canis by PCR analysis. The percentage of
dogs in the negative control group that were infected
was calculated to confirm the success of the model. The
percentage blocking efficacy for the treatment groups
was calculated as follows:
Efficacy (%) = 100 × (Tc − Tt)/Tc, where:
Tc = Total number of infected dogs in the negative
control group.
Tt = Total number of infected dogs in the specific
treatment groups.
The proportion of animals infected in each group was
also compared using the chi-square test or Fischer’s
exact test as applicable. SAS Version 9.3 TS Level 1 M2
was used for all the statistical analyses. The level of sig-
nificance of the formal tests was set at 5%, all tests were
two sided.
Methods: experiment 1
The experiment 1 was designed to evaluate the prevent-
ive efficacy of one spot-on application of fipronil and
permethrin combination (Effitix®, Virbac) in the trans-
mission of B.canis by infected adult D.reticulatus from
day 7 to day 28 after application.
The study was conducted on five groups of seven dogs
each: one negative control, not treated (group 1), one
group treated with the combination on day −28 (group
2), one group treated with the combination on day −21
(group 3), one group treated with the combination on
day −14 (group 4), one group treated with the combin-
ation on day −7 (group 5). Animals were then challenged
with a laboratory-bred B.canis infected D.reticulatus tick
strain on day 0.
All the animals were observed daily from day −35 to
28 for general health conditions and clinical signs of
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hourly for 4 hours post-treatment for possible adverse
events. The study animals were subjected to a clinical
examination on day −35 and 7, 14, 21 and 28 days post
tick challenge. Additionally clinical examinations were
conducted on all dogs displaying clinical signs (elevated
body temperature, anemia, haematuria and/or icterus)
associated with babesiosis.
Rectal body temperatures were recorded daily from
day 6 to 13. Two blood smears were prepared for dogs
displaying abnormally high body temperatures (>39.4°C).
Blood was collected for potential PCR assay on the
Days 14, 21, 28 and from dogs on the day of being diag-
nosed infected with B.canis based on blood smear
evaluations.
Blood was collected for IFA test from all dogs on days
0 (prior to tick challenge), 14, 21 and 28 and serum was
assayed for B.canis antibodies. In situ tick counts were
performed on days 2, 3, 4, 5 and ticks were counted and
removed on day 6.
Methods: experiment 2
The experiment 2 was designed to evaluate the prevent-
ive efficacy of one spot-on application of fipronil and
permethrin combination (Effitix®, Virbac) in the trans-
mission of B.canis by infected adult D.reticulatus two
days after application.
The study was conducted on two groups of eight dogs
each: one negative control and one group of dogs treated
on day-2. Animals were then challenged with a
laboratory-bred B.canis infected D.reticulatus tick strain
on day 0.
All the animals were observed daily from day −9 to 49
(except from days 29 to 32) for general health conditions
and clinical signs of adverse events to treatment. The
dogs were observed hourly for 4 hours post-treatment
for possible adverse events. The study animals were sub-
jected to a clinical examination on day −9 and 6, 13, 21
and +27 days post tick challenge. Additionally clinical
examinations were conducted on all dogs displaying clin-
ical signs (elevated body temperature, anemia, haematuria
and/or icterus) associated with babesiosis.
Rectal body temperatures were recorded daily from
days 7 to 28. Clinical examinations were conducted and
two blood smears prepared for dogs displaying abnor-
mally high body temperatures (>39.4°C).
Blood was collected for potential PCR assay on the
days −9, 0, 13, 21, 27 and from dogs on the day of being
diagnosed infected with B.canis based on blood smear
evaluations. Blood was collected for IFA test from all
dogs on days 0 (prior to tick challenges), 13, 21, 27, 35,
42 and 49 and serum was assayed for B. canis antibodies.
In situ tick counts were performed on days 1, 2, 3 and
ticks were counted and removed on day 6.Results
The novel combination of fipronil and permethrin admin-
istered as topical solution to 36 dogs was well-tolerated by
all animals. No relevant health abnormalities - other than
babesiosis – or local reactions which can be linked to the
treatment, were detected in the treated animals during
both studies.
Results: experiment 1
Acaricidal efficacy against D.reticulatus
An arithmetic mean tick count of 16.6 (33.2% of ticks
infested) was recorded for the untreated negative control
group on day 2 indicating a vigorous tick challenge. Effi-
cacy values (%) based on arithmetic and geometric mean
tick counts for the treated groups are summarized in
Table 2. From 48 h post-infestation up to three weeks
post-treatment, the combination was fully effective
(100%, based on arithmetic means) and it was highly
effective (≥95.7%, based on arithmetic means) against
infestations with D.reticulatus ticks for four weeks
post-treatment (Group 2).
Anti-feeding efficacy against D.reticulatus
The engorgement status of the ticks was evaluated at
each tick count. No engorged tick (dead or alive) was
found on the dogs treated with the combination whereas
a mean of 4.7 ticks (arithmetic mean) was found on the
control group. The numbers of engorged ticks per group
are shown in Figure 1.
B.canis blocking effect
All dogs included in the experiment were tested negative
for B.canis antibodies in the IFA assay prior to tick in-
festation.The infection rate of the ticks used for infest-
ation and confirmed by PCR analysis was high with 28%
of the ticks harbouring B.canis. All untreated control
dogs developed specific antibodies to B.canis and were
positive for B.canis by PCR analysis on one or more
post-challenge timepoints (Table 3). In the treated
groups, only two dogs out of 28 met the criteria of a
clinically significant infection (Table 3). The treatment
did significantly (p < 0.05) lower the risk of infection
with an average of 92.9% in preventing the transmission
of B.canis by infected D.reticulatus over the challenge
period (Table 4).
Results: experiment 2
Acaricidal efficacy against D.reticulatus
An arithmetic mean tick count of 25.5 (51% of ticks
infested) was recorded for the untreated negative control
group on day 2 indicating a vigorous tick challenge. Effi-
cacy values (%) based on arithmetic and geometric mean
tick counts for the treated groups are summarized in
Table 5. The combination was rapidly effective as more
Table 2 Experiment 1: Efficacy values (%) based on arithmetic and geometric mean tick counts for the treated groups
DAY EFFICACIES (%)
GROUP 2 – Treated 28 days prior to tick challenge GROUP 3 – Treated 21 days prior to tick challenge
Arithmetic mean Geometric mean Arithmetic mean Geometric mean
+2 95.7 97.0 100.0 100.0
+3 100.0 100.0 100.0 100.0
+4 100.0 100.0 100.0 100.0
+5 100.0 100.0 100.0 100.0
+6 100.0 100.0 100.0 100.0
DAY EFFICACIES (%)
GROUP 4 – Treated 14 days prior to tick challenge GROUP 5 - Treated 7 days prior to tick challenge
Arithmetic mean Geometric mean Arithmetic mean Geometric mean
+2 100.0 100.0 100.0 100.0
+3 100.0 100.0 100.0 100.0
+4 100.0 100.0 100.0 100.0
+5 100.0 100.0 100.0 100.0
+6 100.0 100.0 100.0 100.0
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and was fully effective as from 72 h post-infestation.
Anti-feeding efficacy against D.reticulatus
The engorgement status of the ticks was evaluated at
each tick count. No engorged tick (dead or alive) was
found on the dogs treated with the combination whereas
a mean of 13.1 ticks (arithmetic mean) was found on the
control group. The numbers of engorged ticks per group
are shown in Figure 2.
B.canis blocking effect
The infection rate of the ticks used for infestation and
confirmed by PCR analysis was high with 12% of the
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Figure 1 Experiment 1: Number of engorged ticks (live or dead) for t
treated on day −28; Group 3: treated on day −21; Group 4: treated on day
on Day 0.were tested negative for B.canis antibodies in the IFA
assay prior to tick infestation. Six dogs out of eight un-
treated control dogs developed specific antibodies to B.
canis and were positive for B.canis by PCR analysis on
one or more post-challenge time points (Table 3). In the
treated groups, no dog met the criteria of a clinically sig-
nificant infection (Table 3). Therefore, the treatment was
regarded to be fully effective in preventing the transmis-
sion of B.canis infected D.reticulatus ticks (100% prevent-
ive efficacy, p = 0.007, see Table 4) over this assessment
period.
Discussion
The principal findings of these studies are that a fixed
combination of permethrin 54.5% and fipronil 6.1%Day 6
llenge
Group 1 (Control)
Group 2 (Effitix® at Day -28)
Group 3 (Effitix® at Day-21)
Group 4 (Effitix® at Day-14)
Group 5 (Effitix® at Day-7)
reated and control groups. Group 1: untreated dogs; Group 2:
−14; Group 5: treated on day −7. All groups were infested with ticks
Table 3 Summary of positive infection with Babesia canis based on PCR and IFA tests results
Group* Animal ID PCR IFA Blood smear** Infected***
Results for experiment 1
Group 1 Untreated 1-1-1 POS POS POS YES
1-1-2 POS POS POS YES
1-1-3 POS POS POS YES
1-1-4 POS POS POS YES
1-1-5 POS POS POS YES
1-1-6 POS POS - YES
1-1-7 POS POS POS YES
Infected = 100%
Group 2 Treated on day −28 1-2-1 NEG NEG - NO
1-2-2 POS POS POS YES
1-2-3 NEG NEG - NO
1-2-4 NEG NEG - NO
1-2-5 NEG NEG - NO
1-2-6 NEG NEG - NO
1-2-7 POS NEG - NO
Infected = 14.3%
Group 3 Treated on day −21 1-3-1 NEG NEG - NO
1-3-2 NEG NEG - NO
1-3-3 NEG NEG - NO
1-3-4 POS NEG - NO
1-3-5 NEG NEG - NO
1-3-6 NEG NEG - NO
1-3-7 NEG NEG - NO
Infected = 0%
Group 4 Treated on day −14 1-4-1 NEG NEG - NO
1-4-2 NEG NEG NEG NO
1-4-3 NEG NEG - NO
1-4-4 NEG NEG - NO
1-4-5 NEG NEG - NO
1-4-6 NEG NEG NEG NO
1-4-7 NEG NEG - NO
Infected = 0%
Group 5 Treated on day −7 1-5-1 NEG NEG - NO
1-5-2 NEG NEG - NO
1-5-3 NEG NEG - NO
1-5-4 NEG NEG - NO
1-5-5 POS NEG - NO
1-5-6 POS POS POS YES
1-5-7 NEG NEG - NO
Infected = 14.3%
Results for experiment 2
Group 1 Untreated 2-1-1 POS NEG POS NO
2-1-2 POS POS POS YES
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Table 3 Summary of positive infection with Babesia canis based on PCR and IFA tests results (Continued)
2-1-3 POS NEG POS NO
2-1-4 POS POS POS YES
2-1-5 POS POS POS YES
2-1-6 POS POS POS YES
2-1-7 POS POS POS YES
2-1-8 POS POS POS YES
Infected = 75%
Group 2 Treated on day −2 2-2-1 NEG NEG NEG NO
2-2-2 NEG NEG NEG NO
2-2-3 NEG NEG NEG NO
2-2-4 NEG NEG NEG NO
2-2-5 NEG NEG NEG NO
2-2-6 NEG NEG NEG NO
2-2-7 NEG NEG NEG NO
2-2-8 NEG NEG NEG NO
Infected = 0%
*Experiment 1: Group 1: untreated dogs ; Group 2: treated on day −28; Group 3: treated on day −21; Group 4: treated on day −14; Group 5: treated on day −7.
Experiment 2: Group 1: untreated dogs ; Group 2: treated on day −2.
All groups were infested with ticks on Day 0.
**Blood smear only prepared if clinical signs observed.
***Dogs declared positive if both IFA and PCR are positive.
POS: dog with a positive IFA or PCR or blood smear analysis.
NEG: dog with a negative IFA or PCR or blood smear analysis.
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prevention of B.canis transmission by infected D.reticu-
latus when administered once monthly to dogs. In
addition, tick mortality was high, with a high percentage
of ticks killed in less than 24 hours and with 100% of all
infested ticks being dead within 3 days post challenge.
Study design
The study design selected presented a very severe chal-
lenge scenario with a vigorous tick infestation for both
studies and ticks presenting high B.canis infection rates.
In particular, in experiment 1 the tick infection rate was
28% (12% in experiment 2). In the field, the infection
rates of D.reticulatus ticks should be considerably less.
Recent surveys conducted in central Europe, where
babesiosis is well represented, showed a prevalence of B.
canis infections in ticks ranging from 2.3% to 14.7% in
Slovakia [2] and 2.5% in the southwest of Germany [20].Table 4 Babesia blocking effect: detailed results for both
studies
Groups (n) Infected* Prevention (%)
Experiment 1 Control (7) 7 -
All treated (28) 2 92.9
Experiment 2 Control (8) 6 -
All treated (8) 0 100
*Dogs declared positive if both IFA and PCR positive.Another advantage of this model is that the challenge
load with infected ticks can be pre-determined and stan-
dardized which is not the case when dogs were either
exposed to infected ticks under field conditions or when
infected ticks were collected from the field and tested on
dogs under controlled laboratory conditions [3].
The study design selected detected exposure to Babe-
sia infection in dogs using four different diagnostic tech-
niques: (a) regular monitoring of body temperature and
health status of all dogs; (b) thin blood smear examin-
ation for B.canis parasites in red blood cells of pyrexic
dogs (>39.4°C); (c) regular molecular assays for detection
of B. canis DNA by PCR; (d) regular serology for B.
canis antibodies. All diagnostic tests have inherent ad-
vantages and limitations. Regular monitoring of body
temperature and health status of the dogs corresponds
to the clinical course of natural infection [1]. BloodTable 5 Experiment 2: efficacy values (%) based on
arithmetic and geometric mean tick counts for the
treated group
Day GROUP 2 – Treated 2 days prior to tick challenge









































Number of days after tick challenge
Group 1 (Control)
Group 2 (Effitix®at Day-2)
Figure 2 Experiment 2: Number of engorged ticks (live or dead) for treated and control groups. Group 1: untreated dogs; Group 2:
treated on day −2. All groups were infested with ticks on Day 0.
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leading to a non-equivocal diagnostic as the piroplasms
are identified. However, the number of intravascular or-
ganisms fluctuates over time following transmission
leading to false negative results for an infected patient.
Serology relies on an immunologically appropriate and
detectable host immune response against one or more
pathogens, one potential limitation being diminution of
specificity due to antibody cross-reactivity and leading to
a false positive result. PCR has the advantage to specific-
ally target a pathogen at the species or strain level [21].
In the two studies, an efficacy failure (dogs effectively
infected) was therefore regarded as a dog in the Effitix®
administration group that was tested positive to display
PCR, as well as IFA positive tests results. Sero-conversion
is influenced by the general immune status of the host.
However, since the dogs enrolled in the study were clinic-
ally healthy, immunosuppression leading to an impaired
antibody response appeared unlikely. In some cases, the
transient minute quantity of B.canis transmitted by in-
fected ticks was detected in dogs by sensitive PCR meth-
odology; however, this was not sufficient to lead to any
further clinical sequelae and development of specific anti-
bodies. Hence, these dogs were not considered clinically
infected. As a result, a combination of both assessment
criteria for clinical infection with B.canis was used: dogs
needed to display PCR as well as IFA positive tests results.
This, ensured a more meaningful evaluation of the trans-
mission blocking effectiveness of the combination.
When compared to the first experiment, the follow-up
period of the animals in the second experiment was ex-
tended up to day 49 post-tick challenge. This change in
the study design was decided in order to adopt a more
conservative approach in the evaluation of the efficacy of
Effitix®. A late stage sero-conversion by days 28–49 may
indicate a low level transmission of B.canis sporozoitesduring a brief attachment by a small number of ticks
without fever or other signs of babesiosis being evident
[15]. In that specific case, even if the treatment did not
completely block the transmission of B.canis in a small
proportion of dogs, it prevents the development of clin-
ical signs of babesiosis. Therefore it can be expected that
the efficacy of Effitix® in preventing the clinical signs of
B.canis in dogs was well evaluated, based on a reliable,
reproducible and highly challenging model and that the
protection rate may be even higher under field condi-
tions where prevalence of B.canis infected ticks is lower.
Acaricidal effect
The combination provided a complete killing of D.reti-
culatus 72 h post-infestation during one month post-
application. In addition, a rapid killing was documented
in experiment 2, as more than 70% of the D.reticulatus
ticks were killed within 24 hours post-infestation. A
complete killing of D. reticulatus was already observed
with the fipronil mono-product spot-on up to six weeks
post-treatment [22] whereas a rapid killing against D.
reticulatus was described with permethrin-based mono-
product spot on formulations [23]. Therefore, it can be
expected that the excellent and persistent acaricidal effect
against D.reticulatus observed in both studies is linked to
the persistent and robust acaricidal properties of fipronil
together with the rapid killing effect of permethrin.
B.canis blocking effect
The blocking effect (92.9% for experiment 1 and 100%
for experiment 2) observed in these studies was similar
to what was recently reported in studies using a labora-
tory transmission blocking model. For example, one oral
anti-flea and tick product containing afoxolaner was
tested on dogs. One dog out of eight was found slightly
positive in the IFA test at day 93 post-treatment whereas
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[17]. Another study involving the combination of fipronil-
amitraz-(S)-methoprene demonstrated 86% efficacy against
transmission using a similar protocol [15]. Another recent
study involving an imidacloprid/flumethrin collar reported
a 100% protection level based on B. canis antibodies de-
tection in eight treated dogs. Similarly, a 100% blocking ef-
fect over a six-months field trial was described with 9%
amitraz-impregnated tick collars against B.canis rossi [24].
It should be noted however that one of the strength of the
data reported in this article is the severity of the parasitical
pressure in the laboratory model selected compared to
field situation, with high tick retention rates combined
with important B.canis infestation levels. Another strength
is the number of dogs involved leading to a total of 36
dogs in treated groups and 15 dogs in the control groups
taking into account the probable host variability in tick re-
tention rate of D.reticulatus and B.canis susceptibility.
The complete and rapid killing of ticks by the tested
combination (acaricidal effect) is of importance with re-
spect to the ability to block transmission of pathogens.
With 100% of all infested ticks being dead within 3 days
post challenge, the combination successfully prevented
transmission of mature Babesia sporozoites into the
treated dogs, whereas they were readily transmitted to
the untreated control group. Furthermore, no engorged
tick (dead or alive) was found for all treated dogs during
the overall assessment period whereas a mean of 4.7
ticks (arithmetic mean) was found on the control group
in experiment 1 and 13.1 ticks (arithmetic mean) in ex-
periment 2. This anti-feeding effect is certainly another
important element in preventing the transmission of
pathogens. When compared to the published data on
the capacity of fipronil and permethrin to provide an
anti-feeding effect, it should be noted that fipronil has
poor anti-feeding properties [13] as dead engorged and
dead attached ticks are found 48 hours post-treatment
when using fipronil spot-on alone [22]. On the contrary,
permethrin is well-known for its repellent effect. Per-
methrin has been shown to be a contact repellent mean-
ing that ectoparasites must come in contact with the
molecule to be affected. It is probable that only a few
minutes of exposure are sufficient to cause the ticks to
move away from treated surfaces while many of them
have received a lethal dose during this period [13,14].
Therefore, it can be expected that the excellent block-
ing effects observed in both studies is not only due to a
complete and rapid killing of the parasites but also to
repellent properties linked to the presence of permethrin
in the combination.
Conclusions
In conclusion, the novel combination of fipronil and per-
methrin was highly effective against challenge with D.reticulatus ticks up to 1 month after application. The
high acaricidal efficacy of the combination combined
with anti-feeding properties resulted in a transmission
protection level ranging from 92.9 % (experiment 1) to
100% (experiment 2) against the clinical signs of B.canis
in dogs. This combination can be used as a part of the
strategy to control flea and tick infestations, in particu-
lar when there is a risk of transmission of vector-borne
diseases.
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